Dr Albert Bourla, Pfizer chairman and CEO said: “Today is a great day for science and humanity.
“The first set of results from our Phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19.
“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.
“With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.
“We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.
“I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavour.
“We could not have come this far without the tremendous commitment of everyone involved.”
Pfizer is developing the mRNA-based vaccine alongside BioNTech and is one of two leading researchers including Oxford University and AstraZeneca.
Last week, it was reported the vaccine DES (Directed Enhanced Service) is set to be rolled out across the UK from the beginning of December.
According to GP’s magazine Pulse, practices and Primary Care Networks (PCN’s) will be asked to give the potential vaccine to over-85s and front line workers as early as next month.
PCN’s are groups of practices working together to focus on local patient care.
Teams will also deliver the potentially life-saving vaccine to care homes and at-scale delivery centres, reports suggest.
More to follow…
